Regen BioPharma, Inc. Announces Presentation at the International Society for Stem Cell Research 13th Annual Meeting in Stockholm, Sweden
SAN DIEGO, Jun. 16, 2015 /PRNewswire/ --Regen BioPharma Inc (OTCBB: RGBP) (OTC PINK: RGBP) announced today that its abstract was accepted for presentation at the International Society for Stem Cell Research Annual Meeting, June 24-27, in Stockholm, Sweden. Dr. Christine Ichim, the Company's Director of Molecular Therapeutics, will be presenting preclinical data delineating the effects of the Company's gene silencing drugs on stem cells.
"The International Society for Stem Cell Research is considered by many to be premier international society for stem cell science and I am very excited to have the opportunity to present my work at the 2015 annual meeting" said Christine Ichim.
The International Society for Stem Cell Research is an organization dedicated to a concerted international approach to advancing research towards new therapies. The 2015 conference will be attended by more than 3,000 scientists, educators, clinicians, and industry professionals from 55 countries.
http://www.isscr.org/home/annual-meeting/isscr2015
ABOUT REGEN BIOPHARMA INC.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) (OTC PINK: RGBP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
www.regenbiopharma.com
SOURCE Regen BioPharma, Inc.
Share this article